Brief: Onesource Specialty Pharma Says Orbicular Secures Tentative U.S. FDA ANDA Approval For Generic Ozempic
21/04/2026 06:35
April 21 (Reuters) - Onesource Specialty Pharma Ltd ONEO.NS: ORBICULAR SECURES TENTATIVE U.S. FDA ANDA APPROVAL FOR GENERIC OZEMPIC Source text: ID:nBSE9gLGJX Further company coverage: ONEO.NS ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Onesource Specialty Pharma
See all newsBrief: Onesource Specialty Pharma Not To Pursue Merger Of Facilities Of Steriscienceat With Co
Brief: Onesource Specialty Pharma March-Quarter Consol Profit 46 Million Rupees
Brief: Onesource Specialty Pharma Says Orbicular Secures Tentative U.S. FDA ANDA Approval For Generic Ozempic
Brief: Onesource Specialty Pharma Says EU-GMP Certification For Unit II Manufacturing Facility Renewed
Brief: Onesource Specialty Says Onesource-Hikma Secures Approval To Commercialise Generic Ozempic In Saudi Arabia